The American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) hosted their virtual meetings, on May 29th-31st and June 11th-21st. While both meetings cover a number of topics in malignant hematology, this issue of CARE™ Perspectives from ASCO / EHA focuses on trials presented in CLL, MM, NHL, and Acute Leukemia.
Click to view the full ASCO EHA publication!
CARE™ Response to COVID-19
The COVID-19 pandemic has disrupted clinical care globally.
A study was conducted with the aim of better understanding the reality of treatment and approaches to education during the current COVID-19 pandemic with consideration of the near-term future (<2 years).
On May 4th, 2020, a survey was emailed and/or mailed to 347 hematologists across Canada. The 10-item survey covered 3 areas: approaches related to delivery of therapy in clinic; near-term impact on patient outcome, and clinician education/knowledge transfer.
Feedback gathered from the assessment showed there is an expressed need for clear guidance on approaches to treatment that considers the impact on patient outcomes before becoming institutionalized at either regional or national levels.
As a follow-up CARE™ Hematology Faculty members connected around the virtual ASCO and EHA conferences to discuss and share approaches to managing patients in the pandemic era, creating a safe treatment environment, and how to better understand education needs moving forward. A CARE™ Guidance publication sharing these insights on management of hematology patients in the COVID-19 era is in development. Areas of focus will include considerations for:
- At clinic
- Specific treatment considerations for CLL, MM, NHL, and HL
A sneak peak at the MM and CLL specific considerations on choice of therapy can be accessed below!